Other disease features that showed an adverse impact on patient OS (p ≤ .05) included: increased (>7.5 ng/ml) carcinoembryonic antigen (CEA) serum levels, larger tumor sizes, histologically poorly-differentiated tumors, lymph node involvement and metastatic liver disease at diagnosis. This evidence concerns the gene CEACAM5 and neoplasm.